AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
SIGNIFICANCE OF CELL-PROLIFERATION MEASUREMENT IN GASTRIC-CANCER
Authors: SCHIPPER DL WAGENMANS MJM PETERS WHM WAGENER DJT
Citation: Dl. Schipper et al., SIGNIFICANCE OF CELL-PROLIFERATION MEASUREMENT IN GASTRIC-CANCER, European journal of cancer, 34(6), 1998, pp. 781-790
5-FLUOROURACIL IN COLORECTAL-CANCER - RATIONALE AND CLINICAL-RESULTS OF FREQUENTLY USED SCHEDULES
Authors: KAMM YJL WAGENER DJT RIETJENS IMCM PUNT CJA
Citation: Yjl. Kamm et al., 5-FLUOROURACIL IN COLORECTAL-CANCER - RATIONALE AND CLINICAL-RESULTS OF FREQUENTLY USED SCHEDULES, Anti-cancer drugs, 9(5), 1998, pp. 371-380
THE ESMO PROGRAM OF CERTIFICATION AND TRAINING FOR MEDICAL ONCOLOGY
Authors: WAGENER DJT VERMORKEN JB HANSEN HH HOSSFIELD DK
Citation: Djt. Wagener et al., THE ESMO PROGRAM OF CERTIFICATION AND TRAINING FOR MEDICAL ONCOLOGY, Annals of oncology, 9(6), 1998, pp. 585-587
IN-VITRO AND IN-VIVO BONE-MARROW TOXICITY ASSAYS IN THE CLINICAL DEVELOPMENT OF NEW DRUGS - CARZELESIN AS AN EXAMPLE
Authors: VANTELLINGEN O SCHAAF LJ PUNT CJA AWADA A VANDERVALK M HENRAR REC WAGENER DJT PICCART MJ NOOIJEN WJ BEIJNEN JH
Citation: O. Vantellingen et al., IN-VITRO AND IN-VIVO BONE-MARROW TOXICITY ASSAYS IN THE CLINICAL DEVELOPMENT OF NEW DRUGS - CARZELESIN AS AN EXAMPLE, Annals of oncology, 9, 1998, pp. 204-204
ENHANCED MYELOTOXICITY DUE TO GRANULOCYTE-COLONY-STIMULATING FACTOR ADMINISTRATION UNTIL 48 HOURS BEFORE THE NEXT CHEMOTHERAPY COURSE IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA
Authors: TJANHEIJNEN VCG BIESMA B FESTEN J SPLINTER TAW COX A WAGENER DJT POSTMUS PE
Citation: Vcg. Tjanheijnen et al., ENHANCED MYELOTOXICITY DUE TO GRANULOCYTE-COLONY-STIMULATING FACTOR ADMINISTRATION UNTIL 48 HOURS BEFORE THE NEXT CHEMOTHERAPY COURSE IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA, Journal of clinical oncology, 16(8), 1998, pp. 2708-2714
A CLINICAL PHARMACOKINETICS STUDY OF CARZELESIN GIVEN BY SHORT-TERM INTRAVENOUS-INFUSION IN A PHASE-I STUDY
Authors: VANTELLINGEN O PUNT CJA AWADA A WAGENER DJT PICCART MJ GROOT Y SCHAAF LJ HENRAR REC NOOIJEN WJ BEIJNEN JH
Citation: O. Vantellingen et al., A CLINICAL PHARMACOKINETICS STUDY OF CARZELESIN GIVEN BY SHORT-TERM INTRAVENOUS-INFUSION IN A PHASE-I STUDY, Cancer chemotherapy and pharmacology, 41(5), 1998, pp. 377-384
QUANTITATIVE ULTRASONIC ANALYSIS OF LIVER METASTASES
Authors: HUISMAN HJ THIJSSEN JM WAGENER DJT ROSENBUSCH GJE
Citation: Hj. Huisman et al., QUANTITATIVE ULTRASONIC ANALYSIS OF LIVER METASTASES, Ultrasound in medicine & biology, 24(1), 1998, pp. 67-77
CORRELATION BETWEEN IODODEOXYURIDINE AND MIB-1 LABELING INDEX IN GASTRIC CARCINOMAS AND ADJACENT NORMAL GASTRIC TISSUE
Authors: SCHIPPER DL WAGENMANS MJM PETERS WHM WOBBES T WAGENER DJT
Citation: Dl. Schipper et al., CORRELATION BETWEEN IODODEOXYURIDINE AND MIB-1 LABELING INDEX IN GASTRIC CARCINOMAS AND ADJACENT NORMAL GASTRIC TISSUE, Gastroenterology, 114(4), 1998, pp. 2779-2779
THE ROLE OF GLUTATHIONE S-TRANSFERASES, P-170 GLYCOPROTEIN, MULTIDRUG-RESISTANCE ASSOCIATED PROTEIN AND IODODEOXYURIDINE LABELING INDEX IN CHEMOTHERAPY RESISTANCE OF STOMACH-CANCER
Authors: SCHIPPER DL WAGENMANS MJM PETERS WHM WILS JAJM WAGENER DJT
Citation: Dl. Schipper et al., THE ROLE OF GLUTATHIONE S-TRANSFERASES, P-170 GLYCOPROTEIN, MULTIDRUG-RESISTANCE ASSOCIATED PROTEIN AND IODODEOXYURIDINE LABELING INDEX IN CHEMOTHERAPY RESISTANCE OF STOMACH-CANCER, Gastroenterology, 114(4), 1998, pp. 2780-2780
GLUTATHIONE S-TRANSFERASES AND CANCER (REVIEW)
Authors: SCHIPPER DL WAGENMANS MJH WAGENER DJT PETERS WHM
Citation: Dl. Schipper et al., GLUTATHIONE S-TRANSFERASES AND CANCER (REVIEW), International journal of oncology, 10(6), 1997, pp. 1261-1264
DOSE INTENSIFICATION OF CHEMOTHERAPY AND THE ROLE OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN SMALL-CELL LUNG-CANCER
Authors: TJANHEIJNEN VCG POSTMUS PE WAGENER DJT
Citation: Vcg. Tjanheijnen et al., DOSE INTENSIFICATION OF CHEMOTHERAPY AND THE ROLE OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN SMALL-CELL LUNG-CANCER, Anti-cancer drugs, 8(6), 1997, pp. 549-564
WEEKLY CHRONOMODULATED 48-H INFUSION OF HIGH-DOSE 5-FLUOROURACIL MODULATED BY METHOTREXATE AND (6S)-LEUCOVORIN IN ADVANCED COLORECTAL-CANCER - A PHASE-IB STUDY
Authors: PUNT CJA KAMM YL WAGENER DJT
Citation: Cja. Punt et al., WEEKLY CHRONOMODULATED 48-H INFUSION OF HIGH-DOSE 5-FLUOROURACIL MODULATED BY METHOTREXATE AND (6S)-LEUCOVORIN IN ADVANCED COLORECTAL-CANCER - A PHASE-IB STUDY, Anti-cancer drugs, 8(5), 1997, pp. 454-458
ADVANCED COLORECTAL-CANCER, REFRACTORY TO INFUSIONAL FLUOROURACIL TREATMENT - EFFICACY OF 2ND LINE FLUOROURACIL IN COMBINATION WITH A DIFFERENT BIOCHEMICAL MODULATION
Authors: VANHALTEREN HK WAGENER DJT VREUGDENHIL G PUNT CJA
Citation: Hk. Vanhalteren et al., ADVANCED COLORECTAL-CANCER, REFRACTORY TO INFUSIONAL FLUOROURACIL TREATMENT - EFFICACY OF 2ND LINE FLUOROURACIL IN COMBINATION WITH A DIFFERENT BIOCHEMICAL MODULATION, Anticancer research, 17(4A), 1997, pp. 2715-2719
THE ROLE OF GLUTATHIONE S-TRANSFERASES, P-170 GLYCOPROTEIN, MULTIDRUG-RESISTANCE ASSOCIATED PROTEIN AND IODODEOXYURIDINE LABELING INDEX IN CHEMOTHERAPY RESISTANCE OF GASTRIC-CANCER
Authors: SCHIPPER DL WAGENMANS MJH PETERS WHM WAGENER DJT
Citation: Dl. Schipper et al., THE ROLE OF GLUTATHIONE S-TRANSFERASES, P-170 GLYCOPROTEIN, MULTIDRUG-RESISTANCE ASSOCIATED PROTEIN AND IODODEOXYURIDINE LABELING INDEX IN CHEMOTHERAPY RESISTANCE OF GASTRIC-CANCER, Gut, 41, 1997, pp. 253-253
RESULTS OF A PHASE-II TRIAL OF EPIRUBICIN AND CISPLATIN (EP) BEFORE AND AFTER IRRADIATION AND 5-FLUOROURACIL IN LOCALLY ADVANCED PANCREATIC-CANCER - AN EORTC GITCCG STUDY
Authors: WAGENER DJT HOOGENRAAD WJ ROUGIER P LUSINCHI A TAAL BG VEENHOF CHN DEGRAEFF A CONROY T CURRAN D SAHMOUD T WILS J
Citation: Djt. Wagener et al., RESULTS OF A PHASE-II TRIAL OF EPIRUBICIN AND CISPLATIN (EP) BEFORE AND AFTER IRRADIATION AND 5-FLUOROURACIL IN LOCALLY ADVANCED PANCREATIC-CANCER - AN EORTC GITCCG STUDY, European journal of cancer, 32A(8), 1996, pp. 1310-1313
CHEMOTHERAPY OF GASTRIC-CANCER
Authors: SCHIPPER DL WAGENER DJT
Citation: Dl. Schipper et Djt. Wagener, CHEMOTHERAPY OF GASTRIC-CANCER, Anti-cancer drugs, 7(2), 1996, pp. 137-149
5-FLUOROURACIL METABOLITE PATTERNS IN VIABLE AND NECROTIC TUMOR AREASOF MURINE COLON-CARCINOMA DETERMINED BY F-19 NMR-SPECTROSCOPY
Authors: KAMM YJL HEERSCHAP A ROSENBUSCH G RIETJENS IMCM VERVOORT J WAGENER DJT
Citation: Yjl. Kamm et al., 5-FLUOROURACIL METABOLITE PATTERNS IN VIABLE AND NECROTIC TUMOR AREASOF MURINE COLON-CARCINOMA DETERMINED BY F-19 NMR-SPECTROSCOPY, Magnetic resonance in medicine, 36(3), 1996, pp. 445-450
PHASE-II TRIAL OF VINORELBINE IN METASTATIC SQUAMOUS-CELL ESOPHAGEAL-CARCINOMA
Authors: CONROY T ETIENNE PL ADENIS A WAGENER DJT PAILLOT B FRANCOIS E BEDENNE L JACOB JH SEITZ JF BLEIBERG H VANPOTTELSBERGHE C VANGLABBEKE M DELGADO FM MERLE S WILS J
Citation: T. Conroy et al., PHASE-II TRIAL OF VINORELBINE IN METASTATIC SQUAMOUS-CELL ESOPHAGEAL-CARCINOMA, Journal of clinical oncology, 14(1), 1996, pp. 164-170
GLUTATHIONE S-TRANSFERASES IN GASTRIC CARCINOMAS AND IN ADJACENT NORMAL GASTRIC EPITHELIUM - IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSES
Authors: SCHIPPER DL WAGENMANS MJM PETERS WHM VANHAELST U WOBBES T VERHOFSTAD AAJ WAGENER DJT
Citation: Dl. Schipper et al., GLUTATHIONE S-TRANSFERASES IN GASTRIC CARCINOMAS AND IN ADJACENT NORMAL GASTRIC EPITHELIUM - IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSES, Anticancer research, 16(6B), 1996, pp. 3721-3724
MULTICENTER PHASE-II PHARMACOLOGICAL EVALUATION OF RHIZOXIN
Authors: MCLEOD HL MURRAY LS WANDERS J SETANOIANS A GRAHAM MA PAVLIDIS N HEINRICH B HUININK WWT WAGENER DJT AAMDAL S VERWEIJ J
Citation: Hl. Mcleod et al., MULTICENTER PHASE-II PHARMACOLOGICAL EVALUATION OF RHIZOXIN, British Journal of Cancer, 74(12), 1996, pp. 1944-1948
ANTITUMOR-ACTIVITY AND RETINOTOXICITY OF ETHYLDESHYDROXY-SPARSOMYCIN IN MICE
Authors: HOFS HP WAGENER DJT DEVOS D OTTENHEIJM HCJ WINKENS HJ BOVEE PHM DEGRIP WJ
Citation: Hp. Hofs et al., ANTITUMOR-ACTIVITY AND RETINOTOXICITY OF ETHYLDESHYDROXY-SPARSOMYCIN IN MICE, European journal of cancer, 31A(9), 1995, pp. 1526-1530
SCHEDULE-DEPENDENT ENHANCEMENT OF ANTITUMOR-ACTIVITY OF ETHYLDESHYDROXY-SPARSOMYCIN IN COMBINATION WITH CLASSICAL ANTINEOPLASTIC AGENTS
Authors: HOFS HP WAGENER DJT DEVALKBAKKER V VANRENNES H DEVOS D DOESBURG WH OTTENHEIJM HCJ DEGRIP WJ
Citation: Hp. Hofs et al., SCHEDULE-DEPENDENT ENHANCEMENT OF ANTITUMOR-ACTIVITY OF ETHYLDESHYDROXY-SPARSOMYCIN IN COMBINATION WITH CLASSICAL ANTINEOPLASTIC AGENTS, Anti-cancer drugs, 6(2), 1995, pp. 277-284
PHASE-II TRIAL OF CPT-11 IN PATIENTS WITH ADVANCED PANCREATIC-CANCER,AN EORTC EARLY CLINICAL-TRIALS GROUP-STUDY
Authors: WAGENER DJT VERDONK HER DIRIX LY CATIMEL G SIEGENTHALER P BUITENHUIS M MATHIEUBOUE A VERWEIJ J
Citation: Djt. Wagener et al., PHASE-II TRIAL OF CPT-11 IN PATIENTS WITH ADVANCED PANCREATIC-CANCER,AN EORTC EARLY CLINICAL-TRIALS GROUP-STUDY, Annals of oncology, 6(2), 1995, pp. 129-132
PALLIATIVE CHEMOTHERAPY WITH CMF AFTER THE SAME ADJUVANT REGIMEN FOR BREAST-CANCER
Authors: GERRITSEN M WAGENER DJT SCHADE RWB BEEX LVAM
Citation: M. Gerritsen et al., PALLIATIVE CHEMOTHERAPY WITH CMF AFTER THE SAME ADJUVANT REGIMEN FOR BREAST-CANCER, Netherlands journal of medicine, 46(3), 1995, pp. 131-135
PRECLINICAL ANTITUMOR-ACTIVITY OF ETHYLDESHYDROXYSPARSOMYCIN IN COMBINATION WITH CISPLATIN
Authors: HOFS HP WAGENER DJT DEVALKBAKKER V VANRENNES H DEVOS D DOESBURG WH OTTENHEIJM HCJ DEGRIP WJ
Citation: Hp. Hofs et al., PRECLINICAL ANTITUMOR-ACTIVITY OF ETHYLDESHYDROXYSPARSOMYCIN IN COMBINATION WITH CISPLATIN, Investigational new drugs, 13(1), 1995, pp. 23-32
Risultati: 1-25 | 26-33